Cal Warriner

Johnson & Johnson Fined $2.2 Billion for Reckless Drug Distribution

One has to wonder how this will play with stockholders. Johnson & Johnson, the healthcare giant, has agreed to pay more than $2.2 billion to settle criminal charges over the marketing of its antipsychotic drug, Risperdal. The company’s Janssen Pharmaceuticals division is accused of marketing the drug to treat elderly patients with dementia, children and the disabled.


This case, brought by the Department of Justice, is a big win for American patients.

Risperdal was approved 20 years ago by the U.S. Food and Drug Administration (FDA) for managing psychotic disorders, not to keep the elderly subdued or children quiet.

In announcing the settlement this week, U.S. Attorney General Eric Holder called it among the largest healthcare fraud settlements in U.S. history.

J&J marketed Risperdal for unapproved uses from 1999 through 2005. And it had help. Omnicare, which dispenses drugs to nursing homes, billed the government for the unapproved drugs, and received kickbacks from Risperdal sales reps to prescribe the drug as well as another antipsychotic, Invega (for the treatment of schizophrenia) and Natrecor, a heart drug, according to a report in Bloomberg.

In announcing the plea and fine, Holder said Johnson & Johnson “recklessly put at risk” the elderly and children. The sales force was offered additional incentives to sell the drug for unapproved uses. Bonuses were based on overall sales, not just the sale of an FDA-approved drug, according to the DOJ.

The government does not like to overpay hundreds of millions of dollars for drugs used in a way not approved by the FDA and at the heart of the conviction is not just the danger presented to the most vulnerable members of society, but in having U.S. taxpayers pick up the tab for the elderly, through Medicare, or the disabled, through Medicaid.

The civil complaint was filed in federal court for the Eastern District of Pennsylvania. J&J says the settlement is not an admission of fault, even though the settlement was filed along with a corporate guilty plea. Specifically, Janssen pled guilty to introducing Risperdal into interstate commerce, a violation of the Food Drug and Cosmetic Act. Besides the fine, the punishment includes pleading guilty to a single misdemeanor for the illegal promotion of Risperdal.

In this case, the civil settlement involved 45 states along with the Department of Justice. Other states, including South Carolina and Louisiana, will file actions separately with fines expected to total into the billions of dollars.

Janssen also agreed to a five-year Corporate Integrity Agreement with the Inspector General of Health and Human Services (HHS), according to the plea.

You have to love corporate integrity. Despite record fines, drug companies do not seem to learn from their mistakes.

Other large settlements include one paid by Pfizer Inc. in 2010 which amounted to $2.3 billion for the improper marketing of 13 drugs. GlaxoSmithKline Plc paid $3 billion amid criminal charges it targeted the depression drug Paxil to children, antidepressant Wellbutrin for unapproved uses and failed to provide a warning of the Avandia diabetes drug.

At the end of the day, even after paying a hefty fine, the balance sheet still generally tilts in the favor of the drug manufacturer, so these examples could be called the cost of doing business, very big business.

This entry was posted in Bad Drugs, Mass Tort News and tagged , , , , , , , , . Bookmark the permalink.

3 Responses to Johnson & Johnson Fined $2.2 Billion for Reckless Drug Distribution

  1. Notice: Undefined property: stdClass::$ID in /mnt/stor1-wc1-dfw1/381744/ on line 93
    Howard Sadwin says:

    Settlement should be synonym for traffic ticket fine. These device manufacturers are repeat offenders for kickbacks, for questionable health care billing, miss leading marketing, the list goes on and on.
    I am 67 years old, I am trying to make rhyme or reason as to how this happened
    to 1000′s of patients and to see it never happens again under the present circumstances.
    The FDA does not have the man power to enforce, follow the existing laws that govern the FDA how are they planning to follow all the new proposals that will better ensure and protect the quality of my (our,your)life.
    Eliminating the corruption in the medical device world, accountability and compensation to patients that have been hurt by a device.
    If we had 100 Dr. Margaret Hamburgs to oversee and implement these new innovative plans, patients may respect the medical device world once again, folks would respect our Government, for taking such a bold move in removing the corruption.
    Most important we would not be at such grave risk, unless we agreed to partake in a patient study. We would be better educated as to products, procedures, post and pre surgery, how to deal with issues that appear to be
    common regardless of manufacturer of metal on metal hip device.
    Howard Sadwin

  2. Pingback: J&J Gets Louisiana’s $258 Million Risperdal Verdict Set Aside - Florida Mass Tort Attorneys, Lawyers | Searcy Mass Torts

  3. Pingback: J&J Gets $1.2 Billion Pass on Risperdal Fine - Florida Mass Tort Attorneys, Lawyers | Searcy Mass Torts

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>